Safety Study for Beta Thalassemia Subjects on PTG-300

• Status: Completed
• Trial end date: 2020-07-31
• Target enrollment: 0
• Participant gender: All

Summary

In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Protagonist Therapeutics; Protagonist Therapeutics, Inc.

Criteria

Inclusion Criteria:

• NTD and TD β-thalassemia subjects who completed Week 12 and Week 16 respectively in Study PTG-300-02.

Exclusion Criteria:

• Subjects who discontinued prematurely from study 300-02 (before Week 12 in NTD and Week 16 in TD).